Want to see JP:4597 full AI Analyst Report?
Solasia Pharma KK (4597) AI Stock Analysis
Solasia Pharma KK
(TSE/TYO:4597)
Solasia's financial health is weak, with persistent losses and cash burn, leading to a low financial performance score. The stock's recent technical momentum is positive but appears overbought, while valuation metrics are unattractive due to lack of profitability. The overall score of 54 reflects a below-average investment profile with significant risks.
Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 72.28M
- Price to Earnings (P/E)
- -8.1
- Beta (1Y)
- 1.25
- Revenue Growth
- 32.42%
- EPS Growth
- 61.00%
- Country
- Japan
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Solasia Pharma KK Business Overview & Revenue Model
Company Description
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil or...
How the Company Makes Money
Solasia Pharma generally makes money through (1) licensing and collaboration agreements for its drug candidates and/or marketed products, under which it may receive upfront payments, development and regulatory milestone payments, and sales-based roya...
Solasia Pharma KK Financial Statement Overview
Summary
Solasia's financials show weak performance: volatile revenues, net losses, and negative cash flows. However, low debt provides some flexibility. Overall high risk.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 388.00M | 429.00M | 316.00M | 617.00M | 1.09B | 559.00M |
| Gross Profit | 158.00M | 171.00M | -10.00M | -163.00M | 128.00M | -121.00M |
| EBITDA | -855.00M | -822.00M | -796.00M | -639.00M | -1.20B | -1.92B |
| Net Income | -900.00M | -876.00M | -1.94B | -1.11B | -2.55B | -2.48B |
Balance Sheet | ||||||
| Total Assets | 1.90B | 2.15B | 1.36B | 2.55B | 3.56B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.39B | 886.00M | 728.00M | 803.00M | 714.00M |
| Total Debt | 78.00M | 159.00M | 25.00M | 60.00M | 37.00M | 84.00M |
| Total Liabilities | 443.00M | 392.00M | 203.00M | 673.00M | 899.00M | 1.17B |
| Stockholders Equity | 1.45B | 1.75B | 1.16B | 1.88B | 2.66B | 2.59B |
Cash Flow | ||||||
| Free Cash Flow | -1.14B | -847.00M | -1.03B | -359.00M | -2.07B | -2.48B |
| Operating Cash Flow | -1.14B | -847.00M | -1.03B | -359.00M | -2.07B | -2.47B |
| Investing Cash Flow | -114.00M | -81.00M | 0 | 2.00M | -418.00M | -164.00M |
| Financing Cash Flow | 995.00M | 1.43B | 1.18B | 275.00M | 2.57B | 361.00M |
Solasia Pharma KK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Negative. The current price of 27.00 is below the 20-day moving average (MA) of 28.30, below the 50-day MA of 29.48, and below the 200-day MA of 29.49, indicating a bearish trend. The MACD of -0.63 indicates Negative momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4597.
Solasia Pharma KK Peers Comparison
Overall Rating
JP:457461Neutral- JP:459754Neutral
JP:489248Neutral
JP:453946.5Neutral
JP:488342Neutral
JP:458239Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4574 | 61Neutral | JPY 13.02B | 18.99 | ― | 1.27% | 13.30% | 66.38% |
| JP:4597 | 54Neutral | JPY 7.37B | -8.11 | -53.67% | ― | 32.42% | 61.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4892 | 48Neutral | JPY 5.64B | -6.87 | ― | ― | 364.72% | 18.43% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4883 | 42Neutral | JPY 3.18B | -1.17 | ― | ― | ― | -5.66% |
| JP:4582 | 39Underperform | JPY 3.72B | -0.48 | ― | ― | -30.58% | 6.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4597 | Solasia Pharma KK | 27.00 | -5.00 | -15.63% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | -100.80 | -6.24% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 260.00 | -15.00 | -5.45% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 44.00 | -71.00 | -61.74% | |
| JP:4883 | Modalis Therapeutics Corporation | 28.00 | -47.00 | -62.67% | |
| JP:4892 | Cyfuse Biomedical K.K. | 559.00 | -26.00 | -4.44% |
Solasia Pharma KK Corporate Events
Solasia Pharma Advances Oncology Portfolio With Partner Shifts and Global Expansion
Solasia Pharma reported its second-quarter update for the fiscal year ending December 31, 2026, highlighting progress across its marketed products and development pipeline in oncology and supportive care. The company is also advancing several early-s...
Solasia Pharma Widens Mid-Year Loss and Scraps Full-Year Forecast Amid Revenue Slump
Solasia Pharma reported consolidated sales of ¥8 million for the six months ended June 30, 2026, an 82.5% year-on-year decline, and an operating loss of ¥570 million, leaving net profit attributable to owners of the parent at a loss of ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026